-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 29, seven listed pharmaceutical companies on the Shenzhen Stock Exchange collectively released the 2022 semi-annual announcement, namely Tailin Biological, Xingqi Eye Medicine, Dongbao Pharmaceutical, Northeast Biologics, Northeast Pharmaceutical, Kefu Medical, Aokangsai, and Aoyuan Meigu
Overall, most of them showed a growth trend, and its Middle East Treasure Bio performed the most eye-catching, with a net profit of 667.
Tailin Bio: Net profit increased by 13.
Tailin Bio: Net profit increased by 13.
Xingqi Eye Medicine: Net profit increased by 50.
Xingqi Eye Medicine: Net profit increased by 50.
Northeast Pharmaceutical: Net profit increased by 86.
Northeast Pharmaceutical: Net profit increased by 86.
Toho Biotech: Net profit increased by 667.
Toho Biotech: Net profit increased by 667.
Kefu Medical: Net profit decreased by 39.
Kefu Medical: Net profit decreased by 39.
Aosaicon: Net profit decreased by 95.
Aosaicon: Net profit decreased by 95.
Aoyuan Meigu: Net profit decreased by 256.
Aoyuan Meigu: Net profit decreased by 256.
280 pharmaceutical companies released semi-annual reports, most of which showed an upward trend